PE-22-28 — the short neuropeptide for mood, memory, and cognitive resilience

PE-22-28 doesn't have a brand name or a pharmacy stock number. It's a research peptide, preclinical in its most rigorous characterizations and not FDA-approved, and it's probably not something most clinicians have heard of. But the mechanism it operates through is one of the more interesting recent developments in the neuropharmacology of mood and cognitive function — not because it does something new, exactly, but because it targets a channel that researchers have been trying to figure out how to block in a useful way for fifteen years.

The story starts with an ion channel called TREK-1.

TREK-1 is a member of the two-pore domain potassium channel family — sometimes called background potassium channels or leak channels — and its role is essentially tonic inhibition of neuronal excitability. When TREK-1 is open, potassium ions flow out of the neuron, the cell becomes hyperpolarized, and it's harder to fire. When TREK-1 is closed or inhibited, the neuron becomes more excitable, more responsive, more active. TREK-1 is expressed across a wide range of brain regions, but its expression in the raphe nuclei — the brainstem structures that serve as the primary source of serotonin for the forebrain — attracted the particular attention of researchers interested in depression.

Catherine Heurteaux and colleagues at the CNRS in France published work beginning around 2010 showing that mice genetically lacking TREK-1 exhibited a phenotype that looked, by standard rodent behavioral measures, like an antidepressant state. They were less immobile in forced swim tests, less passive in tail suspension tests, more exploratory in open-field paradigms, and their serotonergic signaling appeared enhanced relative to wild-type animals. The inference was that TREK-1 normally acts as a brake on the serotonin system — by keeping raphe neurons in a state of relative inhibition — and that removing that brake led to increased serotonin release and an antidepressant-like behavioral profile. This suggested that pharmacological TREK-1 blockade might work as a fast-acting antidepressant mechanism, with kinetics potentially different from SSRIs, which need weeks to produce their effects.

The mechanism made sense. SSRIs work by blocking serotonin reuptake — they keep serotonin in the synapse longer by preventing its transport back into the presynaptic neuron. TREK-1 inhibition would work upstream of that: it would increase the firing rate of serotonin-producing neurons in the first place, leading to more serotonin released into terminal projections in the prefrontal cortex, hippocampus, and other structures that regulate mood and cognition. In principle, more serotonin released at the source is a different intervention than less serotonin removed at the destination. Whether this produces meaningfully faster or different antidepressant effects in humans has not been established — but the logic drew interest from researchers looking for new entry points into the pharmacology of depression.

Spadin is an endogenous peptide produced in the brain from the cleavage of a protein called sortilin. Sortilin is a sorting receptor involved in the trafficking of various proteins, and when it's processed, one of the fragments produced is a short propeptide that, in rodent studies, turns out to block TREK-1. This was a surprising finding: the brain appeared to produce its own TREK-1 inhibitor as part of normal biochemical processing. The natural peptide was unstable and short-lived, which limited its therapeutic utility as a direct compound. But it provided a structural template.

PE-22-28 is a truncated, modified version of spadin — shorter and more stable than the natural peptide, engineered to retain TREK-1 blocking activity while being more amenable to research use. The number refers to residues 22 through 28 of spadin's sequence, which the researchers identified as sufficient for channel-blocking activity. In cell studies and rodent models, PE-22-28 blocks TREK-1 with greater potency and stability than the parent fragment. The behavioral effects in standard rodent models of depression — forced swim, tail suspension, sucrose preference tests — showed antidepressant-like effects, and some studies in animal models also showed effects on memory consolidation and contextual learning.

The memory angle connects to TREK-1's broader expression pattern. TREK-1 channels are present in hippocampal neurons, where they regulate excitability in structures central to memory encoding and consolidation. If TREK-1 sets a baseline level of neuronal inhibition in the hippocampus as it does in the raphe, reducing that inhibition could in principle support the kind of neuronal plasticity that underlies learning and memory. This is the proposed mechanism for the cognitive effects observed in rodent models — not stimulant-like arousal, but something closer to increased synaptic responsiveness in memory-relevant circuits. The evidence here is entirely preclinical and involves significant interpretive leaps when applied to humans, but it's the mechanistic basis for interest in PE-22-28 in nootropic and cognitive-support contexts.

The neuroprotective angle also appears in some of the preclinical literature. TREK-1 inhibition may reduce neuronal vulnerability to ischemia in certain models — the same mechanism by which TREK-1 normally limits excitability may, under ischemic conditions, contribute to excitotoxic cell death when the channel fails or is overwhelmed. Preclinical work has looked at TREK-1 as a target in ischemic neuroprotection, though the data are less developed and the clinical relevance is unclear.

Where this sits in the experimental compound landscape is an honest question. PE-22-28 is a research peptide. The studies that exist are in cell cultures and rodents, conducted by academic laboratories interested in the basic science of TREK-1 and sortilin-derived peptides. There are no published human clinical trials. The behavioral effects observed in rodents translate to human outcomes at an uncertain rate — standard rodent depression models have a poor track record of predicting antidepressant efficacy in humans, and the history of promising preclinical mechanisms that failed in human trials is long and well-documented. TREK-1 blockade as an antidepressant strategy is interesting and mechanistically coherent, but it has not been validated in a clinical population.

The consumer interest in PE-22-28 lives in the experimental nootropic community — people who follow peptide pharmacology closely, who are familiar with the limitations of preclinical data and comfortable working at the frontier of unpublished or early-stage research, and who are exploring compounds that operate through mechanisms not represented in the approved pharmacopoeia. For that context, the TREK-1 mechanism is genuinely novel and the spadin-derived peptide approach is a creative solution to the delivery problem that small-molecule TREK-1 blockers have faced (most small molecules that block the channel have off-target effects that complicate their development). PE-22-28 isn't an approved drug, it isn't a supplement with an NCCIH dossier, and it isn't something you'd encounter through a standard prescribing pathway. It's a research compound with an interesting mechanism and a preclinical signal that has attracted enough attention to keep researchers working on it.

There are practical realities worth being specific about. PE-22-28 has no established human dose, no human pharmacokinetic data in the published literature, no clinical safety profile from controlled trials. The stability and bioavailability of the peptide through different delivery routes in humans hasn't been clinically characterized in published research. Anyone working with PE-22-28 is working with preclinical data applied to a human context that those data were not designed to address. This doesn't mean the mechanism is irrelevant — the TREK-1 biology is real, the CNRS work is peer-reviewed, and the spadin-derivation story is well-characterized at the molecular level. It means the translation gap from rodent behavioral models to human therapeutic use is genuinely uncertain and shouldn't be obscured.

What makes PE-22-28 worth understanding, even at this early stage, is what it represents mechanistically rather than what it can currently be claimed to do. Most existing pharmacological approaches to mood and cognitive function work through the big neurotransmitter systems — serotonin, dopamine, norepinephrine, GABA — and they work at the level of receptor binding, reuptake blockade, or enzyme inhibition. Ion channels as direct therapeutic targets are underrepresented in approved neuropsychiatric pharmacology, and the two-pore domain potassium channels are almost entirely unexploited. The idea that a brain-derived peptide fragment — a molecule the brain produces itself through routine protein processing — might hold a key to that channel, and that a shortened version of that fragment might be a useful research compound, is the kind of finding that tends to look obvious in retrospect when something eventually works.

The question the mechanism raises is whether what the brain produces as a normal part of sortilin cleavage is doing exactly what PE-22-28 is proposed to do: modulating a TREK-1 brake on serotonin neurons in some homeostatic way. If so, the implications for what goes wrong in depression, and why, extend well beyond the peptide itself.